These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo. Yan S; Li Z; Thiele CJ Oncotarget; 2013 Mar; 4(3):433-45. PubMed ID: 23531921 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice. Stuart E; Buchert M; Putoczki T; Thiem S; Farid R; Elzer J; Huszar D; Waring PM; Phesse TJ; Ernst M Mol Cancer Ther; 2014 Feb; 13(2):468-74. PubMed ID: 24398427 [TBL] [Abstract][Full Text] [Related]
5. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517 [TBL] [Abstract][Full Text] [Related]
6. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010 [TBL] [Abstract][Full Text] [Related]
7. The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment. Albino D; Civenni G; Rossi S; Mitra A; Catapano CV; Carbone GM Oncotarget; 2016 Nov; 7(47):76756-76768. PubMed ID: 27732936 [TBL] [Abstract][Full Text] [Related]
8. AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway. Wang SW; Hu J; Guo QH; Zhao Y; Cheng JJ; Zhang DS; Fei Q; Li J; Sun YM Oncol Rep; 2014 Nov; 32(5):1991-8. PubMed ID: 25216185 [TBL] [Abstract][Full Text] [Related]
9. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Hedvat M; Huszar D; Herrmann A; Gozgit JM; Schroeder A; Sheehy A; Buettner R; Proia D; Kowolik CM; Xin H; Armstrong B; Bebernitz G; Weng S; Wang L; Ye M; McEachern K; Chen H; Morosini D; Bell K; Alimzhanov M; Ioannidis S; McCoon P; Cao ZA; Yu H; Jove R; Zinda M Cancer Cell; 2009 Dec; 16(6):487-97. PubMed ID: 19962667 [TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Xin H; Herrmann A; Reckamp K; Zhang W; Pal S; Hedvat M; Zhang C; Liang W; Scuto A; Weng S; Morosini D; Cao ZA; Zinda M; Figlin R; Huszar D; Jove R; Yu H Cancer Res; 2011 Nov; 71(21):6601-10. PubMed ID: 21920898 [TBL] [Abstract][Full Text] [Related]
11. IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling. Subotički T; Mitrović Ajtić O; Beleslin-Čokić BB; Bjelica S; Djikić D; Diklić M; Leković D; Gotić M; Santibanez JF; Noguchi CT; Čokić VP Cell Biol Int; 2019 Feb; 43(2):192-206. PubMed ID: 30571852 [TBL] [Abstract][Full Text] [Related]
12. JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation. Lu Z; Hong CC; Jark PC; Assumpção ALFV; Bollig N; Kong G; Pan X J Vet Intern Med; 2017 Nov; 31(6):1804-1815. PubMed ID: 28960447 [TBL] [Abstract][Full Text] [Related]
13. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Chang Q; Bournazou E; Sansone P; Berishaj M; Gao SP; Daly L; Wels J; Theilen T; Granitto S; Zhang X; Cotari J; Alpaugh ML; de Stanchina E; Manova K; Li M; Bonafe M; Ceccarelli C; Taffurelli M; Santini D; Altan-Bonnet G; Kaplan R; Norton L; Nishimoto N; Huszar D; Lyden D; Bromberg J Neoplasia; 2013 Jul; 15(7):848-62. PubMed ID: 23814496 [TBL] [Abstract][Full Text] [Related]
14. Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology. Loveless ME; Lawson D; Collins M; Nadella MV; Reimer C; Huszar D; Halliday J; Waterton JC; Gore JC; Yankeelov TE Neoplasia; 2012 Jan; 14(1):54-64. PubMed ID: 22355274 [TBL] [Abstract][Full Text] [Related]
15. Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Houghton PJ; Kurmasheva RT; Lyalin D; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Smith MA Pediatr Blood Cancer; 2014 Nov; 61(11):1972-9. PubMed ID: 25131802 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. McFarland BC; Ma JY; Langford CP; Gillespie GY; Yu H; Zheng Y; Nozell SE; Huszar D; Benveniste EN Mol Cancer Ther; 2011 Dec; 10(12):2384-93. PubMed ID: 22027691 [TBL] [Abstract][Full Text] [Related]
18. Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3. Sun J; Du Y; Zhang X; Wang Z; Lin Y; Song Q; Wang X; Guo J; Li S; Nan J; Yang J Invest New Drugs; 2020 Aug; 38(4):1003-1011. PubMed ID: 31612426 [TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 promotes proliferative vitreoretinopathy by inducing epithelial-mesenchymal transition via the JAK1/STAT3 signaling pathway. Chen X; Yang W; Deng X; Ye S; Xiao W Mol Vis; 2020; 26():517-529. PubMed ID: 32818015 [TBL] [Abstract][Full Text] [Related]
20. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]